Drugs / STM-416
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05710848 | Jul 2023 → May 2026 overdue | non-invasive bladder urothelial carcinoma | SURGE Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STM-416 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05710848 ↗ |